These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 11027918)

  • 1. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy.
    Okura M; Riehl J; Mignot E; Nishino S
    Neuropsychopharmacology; 2000 Nov; 23(5):528-38. PubMed ID: 11027918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D2 mechanisms in canine narcolepsy.
    Nishino S; Arrigoni J; Valtier D; Miller JD; Guilleminault C; Dement WC; Mignot E
    J Neurosci; 1991 Sep; 11(9):2666-71. PubMed ID: 1831837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narcoleptic canines display periodic leg movements during sleep.
    Okura M; Fujiki N; Ripley B; Takahashi S; Amitai N; Mignot E; Nishino S
    Psychiatry Clin Neurosci; 2001 Jun; 55(3):243-4. PubMed ID: 11422858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
    Shelton J; Nishino S; Vaught J; Dement WC; Mignot E
    Sleep; 1995 Dec; 18(10):817-26. PubMed ID: 8746387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
    Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
    Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy.
    Nishino S; Shelton J; Renaud A; Dement WC; Mignot E
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1170-5. PubMed ID: 7891329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
    Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
    Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE.
    Nishino S; Okura M; Mignot E
    Sleep Med Rev; 2000 Feb; 4(1):57-99. PubMed ID: 12531161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central administration of vitamin B12 aggravates cataplexy in canine narcolepsy.
    Honda K; Riehl J; Inoué S; Mignot E; Nishino S
    Neuroreport; 1997 Dec; 8(18):3861-5. PubMed ID: 9462456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Narcolepsy].
    Billiard M; Cadilhac J
    Rev Neurol (Paris); 1985; 141(8-9):515-27. PubMed ID: 2868518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiology of narcolepsy-cataplexy syndrome.
    Aldrich MS
    Int J Neurol; 1991-1992; 25-26():29-40. PubMed ID: 11980061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy.
    Peever J
    Arch Ital Biol; 2011 Dec; 149(4):454-66. PubMed ID: 22205591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans.
    Nishino S; Riehl J; Hong J; Kwan M; Reid M; Mignot E
    Neurosci Res; 2000 Dec; 38(4):437-46. PubMed ID: 11164570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy.
    Nishino S; Arrigoni J; Shelton J; Kanbayashi T; Dement WC; Mignot E
    J Neurosci; 1997 Aug; 17(16):6401-8. PubMed ID: 9236248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate.
    Mamelak M
    Prog Neurobiol; 2009 Oct; 89(2):193-219. PubMed ID: 19654034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine.
    Reid MS; Tafti M; Nishino S; Sampathkumaran R; Siegel JM; Mignot E
    Brain Res; 1996 Sep; 733(1):83-100. PubMed ID: 8891251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does memory impairment exist in narcolepsy-cataplexy?
    Aguirre M; Broughton R; Stuss D
    J Clin Exp Neuropsychol; 1985 Feb; 7(1):14-24. PubMed ID: 3980679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in the psychopharmacological management of the narcoleptic patient].
    Salín-Pascual RJ; de la Fuente JR
    Acta Psiquiatr Psicol Am Lat; 1985 Mar; 31(1):62-8. PubMed ID: 4050495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected].
    Honda K; Riehl J; Mignot E; Nishino S
    Neuroreport; 1999 Sep; 10(14):3111-8. PubMed ID: 10549832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.
    Black SW; Morairty SR; Chen TM; Leung AK; Wisor JP; Yamanaka A; Kilduff TS
    J Neurosci; 2014 May; 34(19):6485-94. PubMed ID: 24806675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.